|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease.
|
7700274 |
1994 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The APOE variation, prominent in other neurological diseases, showed no influence on MS susceptibility, despite its location within the chromosome 19q13.2 region.
|
9333267 |
1997 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation.
|
9702689 |
1998 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous studies did not show significant differences in the APOE allele frequencies in multiple sclerosis compared with controls but did not examine for correlation with disease severity.
|
10406990 |
1999 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The AA homozygous state of the -491 A/T polymorphism of the APOE regulatory region is associated with cognitive impairment in patients with MS.
|
10536914 |
1999 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
APOE genotyping was determined by polymerase chain reaction and restriction enzyme digestion in 47 patients with MS who had been followed up every 3 months for 2 years as part of an open-label clinical trial with glatiramer acetate.
|
10593303 |
1999 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In multiple sclerosis the concentration of APOE in cerebrospinal fluid and its intrathecal synthesis is reduced.
|
10694843 |
2000 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis.
|
10864599 |
2000 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The APOE allele frequencies of the cases of MS (epsilon2 = 0.06, epsilon3 = 0.8, epsilon4 = 0.13) resembled those of controls.
|
10888365 |
2000 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to examine if apoE polymorphism or apoE levels contribute to the severity of the disease in patients with multiple sclerosis or the outcome of nerve damage in patients with herpes zoster infection.
|
10949525 |
2000 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The rate of progression was significantly faster in the APOE-epsilon 4/epsilon 4 homozygotes compared to other genotypes in the MS group (P<0.05).
|
10962542 |
2000 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis.
|
11109009 |
2000 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
|
11552016 |
2001 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
|
11552016 |
2001 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
An analysis of disease progression in 614 patients with MS from 379 families indicated that APOE-4 carriers are more likely to be affected with severe disease (P=.03), whereas a higher proportion of APOE-2 carriers exhibit a mild disease course (P=.02).
|
11836653 |
2002 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
An analysis of disease progression in 614 patients with MS from 379 families indicated that APOE-4 carriers are more likely to be affected with severe disease (P=.03), whereas a higher proportion of APOE-2 carriers exhibit a mild disease course (P=.02).
|
11836653 |
2002 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
According to the results of previous studies, APOE epsilon4 does not increase the risk of developing MS, but it may influence disease progression and ultimate disability.
|
11990879 |
2002 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed (1)H-MRS of the central portion of both hemispheres and APOE genotyping in 72 patients (52 women and 20 men; mean +/- SD age, 34.8 +/- 8.8 years) with clinically definite relapsing-remitting MS.
|
12533090 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inheritance of the apolipoprotein E (APOE) epsilon4 allele is associated with increased risk of Alzheimer disease, progression to disability in multiple sclerosis, and poor outcome after traumatic brain injury.
|
12810485 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the low rate of epsilon4 allele in Japan should be taken into consideration, our results showed no relation between APOE gene polymorphisms and Japanese patients with MS.
|
12926843 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein E genotype does not influence the progression of multiple sclerosis.
|
14504972 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors studied the association of an exon 4 (E4*epsilon2/3/4) and three promoter polymorphisms of APOE with disease course and severity stratified by gender in 221 patients with multiple sclerosis from two overlapping population-based prevalence cohorts.
|
15007140 |
2004 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Apolipoprotein E (APOE)-epsilon4 has been associated with an unfavorable course of multiple sclerosis (MS).
|
15048896 |
2004 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accelerated brain tissue loss and a higher proportion of lesions evolving into BH therefore provide magnetic resonance imaging evidence for more pronounced tissue destruction in MS patients with APOE-epsilon4.
|
15048896 |
2004 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Apolipoprotein E (APOE)-epsilon4 has been associated with an unfavorable course of multiple sclerosis (MS).
|
15048896 |
2004 |